Comparative Effectiveness of Biologic Therapies for Psoriasis: Insights from a Systematic Review and Meta-Analysis
Dermatology and Dermatitis · 28.12.2023 · 9 (1) · 01-17
DOI: 10.31579/2578-8949/210 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Dermatology and Dermatitis, online erschienen am 28.12.2023. Verfasst von Ahmed Adel Ali Ali * und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Psoriasis is a chronic immune-mediated inflammatory disease that significantly impairs quality of life and requires long-term management. Biologic therapies targeting cytokines such as TNF-α, IL-12/23, and IL-17 have revolutionized treatment. However, concerns remain regarding their long-term efficacy and safety, particularly for rare adverse events and sustained clinical response.
Objective
To evaluate and compare the long-term efficacy and safety of biologic therapies—specifically anti-TNF-α and IL-12/23 inhibitors—in patients with moderate to severe psoriasis.
Methods
An observational systematic review and meta-analysis was conducted including cohort and case-control studies of adult patients treated for ≥1 year. Databases including PubMed, Web of Science, and Google Scholar were searched. Primary outcomes included PASI 75 response rates and serious adverse events (infections, malignancy, and major adverse cardiovascular events). Statistical analysis was performed using a random-effects model.
Results
IL-12/23 inhibitors demonstrated higher efficacy than anti-TNF-α agents, achieving PASI 75 in 84% vs. 76.18% at year 1. Long-term response with IL-12/23 inhibitors remained stable (~80–91%). Rates of serious infections (2.4% vs. 2.9%) and malignancy (3.9% vs. 3.7%) were comparable between groups. IL-12/23 inhibitors showed lower rates of common adverse events (9.22%) compared to anti-TNF-α (25.77%). No significant differences were observed in major cardiovascular events.
Conclusions
IL-12/23 inhibitors provide superior efficacy with a favorable safety profile compared to anti-TNF-α therapies. Both classes show similar risks for serious adverse events, but anti-TNF-α agents are associated with higher rates of common side effects.
Zitieren
APA
*, A. A. A. A., Atef, A., & Gamal, O. (2023). Comparative Effectiveness of Biologic Therapies for Psoriasis: Insights from a Systematic Review and Meta-Analysis. Dermatology and Dermatitis, 9(1), 01-17. https://doi.org/10.31579/2578-8949/210
Vancouver
* AAAA, Atef A, Gamal O. Comparative Effectiveness of Biologic Therapies for Psoriasis: Insights from a Systematic Review and Meta-Analysis. Dermatology and Dermatitis. 2023;9(1):01-17. doi:10.31579/2578-8949/210
BibTeX
@article{2023,
author = {*, Ahmed Adel Ali Ali and Atef, Aliaa and Gamal, Omnya},
title = {Comparative Effectiveness of Biologic Therapies for Psoriasis: Insights from a Systematic Review and Meta-Analysis},
journal = {Dermatology and Dermatitis},
year = {2023},
volume = {9},
number = {1},
pages = {01--17},
doi = {10.31579/2578-8949/210}
}
EUVIMED